Search Within

Mary Philip

Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Sloan Kettering Institute Postdocs (7)
  2. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)
  3. GSK Faculty (6)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (4)
  5. Sloan Kettering Institute Faculty (4)
  6. Computational and Structural Biology Program Faculty (3)

More Groups

People
  1. Andrea Schietinger (6)
  2. Agnes Viale (3)
  3. Christina Leslie (3)
  4. Liping Sun (3)
  5. Andrew Scott (2)
  6. Jedd Wolchok (2)

More People

Years
  1. 2019 (1)
  2. 2017 (1)
  3. 2016 (4)
  4. 2015 (1)
Publications
  1. Blood (2)
  2. Nature (2)
  3. Immunity (1)
  4. Journal of Immunology (1)
  5. Trends in Immunology (1)
Publishers
  1. American Society of Hematology (2)
  2. Nature Publishing Group (2)
  3. Cell Press (1)
  4. Elsevier Inc. (1)
  5. The American Association of Immunologists, Inc (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TOX is a critical regulator of tumour-specific T cell differentiation
    Journal Article

    Scott, A. C.; Dündar, F.; Zumbo, P.; Chandran, S. S.; Klebanoff, C. A.; Shakiba, M.; Trivedi, P.; Menocal, L.; Appleby, H.; Camara, S.; more...
    Nature (2019)

    Fulltext@MSK | Save
  • Chromatin states define tumour-specific T cell dysfunction and reprogramming
    Journal Article

    Philip, M.; Fairchild, L.; Sun, L.; Horste, E. L.; Camara, S.; Shakiba, M.; Scott, A. C.; Viale, A.; Lauer, P.; Merghoub, T.; more...
    Nature (2017)

    Fulltext@MSK | Save
  • Chromatin state dynamics underlying CD8 T cell differentiation and dysfunction in cancer
    Meeting Abstract

    Philip, M.; Fairchild, L.; Sun, L.; Viale, A.; Merghoub, T.; Wolchok, J. D.; Leslie, C. S.; Schietinger, A.
    Blood (2016)

    Fulltext@MSK | Save
  • Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL): Initial results of a phase I/II trial
    Meeting Abstract

    Cassaday, R. D.; Fromm, J.; Cowan, A. J.; Libby, E. N. 3rd; Philip, M.; Behnia, S.; Nartea, M.; Press, O.; Gopal, A. K.
    Blood (2016)

    Fulltext@MSK | Save
  • Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis
    Journal Article

    Schietinger, A.; Philip, M.; Krisnawan, V. E.; Chiu, E. Y.; Delrow, J. J.; Basom, R. S.; Lauer, P.; Brockstedt, D. G.; Knoblaugh, S. E.; Hämmerling, G. J.; more...
    Immunity (2016)

    Fulltext@MSK | Save
  • Deciphering the epigenetic programming underlying CD8 T cell dysfunction in solid tumors
    Meeting Abstract

    Philip, M.; Fairchild, L.; Sun, L.; Viale, A.; Leslie, C.; Schietinger, A.
    Journal of Immunology (2016)

    Fulltext@MSK | Save
  • Beyond genomics: Multidimensional analysis of cancer therapy resistance
    Journal Article

    Philip, M.; Schietinger, A.
    Trends in Immunology (2015)

    Fulltext@MSK | Save